-
Je něco špatně v tomto záznamu ?
Induction of Mild Hyperbilirubinemia: Hype or Real Therapeutic Opportunity?
L. Vitek, C. Bellarosa, C. Tiribelli,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Grantová podpora
NV16-27317A
MZ0
CEP - Centrální evidence projektů
PubMed
30588615
DOI
10.1002/cpt.1341
Knihovny.cz E-zdroje
- MeSH
- bilirubin biosyntéza MeSH
- diabetes mellitus 2. typu prevence a kontrola MeSH
- Gilbertova nemoc patofyziologie MeSH
- glukuronosyltransferasa genetika MeSH
- hyperbilirubinemie epidemiologie genetika patofyziologie MeSH
- kardiovaskulární nemoci prevence a kontrola MeSH
- lidé MeSH
- mediátory zánětu antagonisté a inhibitory MeSH
- metabolický syndrom prevence a kontrola MeSH
- oxidační stres fyziologie MeSH
- sexuální faktory MeSH
- stupeň závažnosti nemoci MeSH
- věkové faktory MeSH
- životní styl MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Observational epidemiological studies showed that mild hyperbilirubinemia has beneficial effects on the prevention of cardiovascular disease, type 2 diabetes mellitus, and metabolic syndrome. In mammals, bilirubin plays a major role as a potent antioxidant. Uridine 5'-diphospho-glucuronosyl transferase (UGT)1A1 variants coding for bilirubin UDP-glucuronosyl transferase resulting in mild hyperbilirubinemia (as in Gilbert syndrome (GS)) may confer a strong genetic advantage. Strategies to boost bioavailability of bilirubin or to mimic GS represent an attractive approach to prevent many oxidative stress and inflammation-mediated diseases. Even a tiny, micromolar increase in serum bilirubin concentrations substantially decreases the risk of oxidative stress-mediated diseases. There are several possible ways to achieve this, including lifestyle changes, changes in dietary patterns, regular physical activities, or use of chemical drug or of specific plant products either in the form of regular food items or nutraceuticals. Further basic and experimental research is required to fully uncover this promising therapeutic field.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023688
- 003
- CZ-PrNML
- 005
- 20201214130834.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/cpt.1341 $2 doi
- 035 __
- $a (PubMed)30588615
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Vitek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics and 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
- 245 10
- $a Induction of Mild Hyperbilirubinemia: Hype or Real Therapeutic Opportunity? / $c L. Vitek, C. Bellarosa, C. Tiribelli,
- 520 9_
- $a Observational epidemiological studies showed that mild hyperbilirubinemia has beneficial effects on the prevention of cardiovascular disease, type 2 diabetes mellitus, and metabolic syndrome. In mammals, bilirubin plays a major role as a potent antioxidant. Uridine 5'-diphospho-glucuronosyl transferase (UGT)1A1 variants coding for bilirubin UDP-glucuronosyl transferase resulting in mild hyperbilirubinemia (as in Gilbert syndrome (GS)) may confer a strong genetic advantage. Strategies to boost bioavailability of bilirubin or to mimic GS represent an attractive approach to prevent many oxidative stress and inflammation-mediated diseases. Even a tiny, micromolar increase in serum bilirubin concentrations substantially decreases the risk of oxidative stress-mediated diseases. There are several possible ways to achieve this, including lifestyle changes, changes in dietary patterns, regular physical activities, or use of chemical drug or of specific plant products either in the form of regular food items or nutraceuticals. Further basic and experimental research is required to fully uncover this promising therapeutic field.
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a bilirubin $x biosyntéza $7 D001663
- 650 _2
- $a kardiovaskulární nemoci $x prevence a kontrola $7 D002318
- 650 _2
- $a diabetes mellitus 2. typu $x prevence a kontrola $7 D003924
- 650 _2
- $a Gilbertova nemoc $x patofyziologie $7 D005878
- 650 _2
- $a glukuronosyltransferasa $x genetika $7 D014453
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperbilirubinemie $x epidemiologie $x genetika $x patofyziologie $7 D006932
- 650 _2
- $a mediátory zánětu $x antagonisté a inhibitory $7 D018836
- 650 _2
- $a životní styl $7 D008019
- 650 _2
- $a metabolický syndrom $x prevence a kontrola $7 D024821
- 650 _2
- $a oxidační stres $x fyziologie $7 D018384
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a sexuální faktory $7 D012737
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bellarosa, Cristina $u Fondazione Italiana Fegato ONLUS, AREA Science Park-Basovizza, Trieste, Italy.
- 700 1_
- $a Tiribelli, Claudio $u Fondazione Italiana Fegato ONLUS, AREA Science Park-Basovizza, Trieste, Italy.
- 773 0_
- $w MED00001155 $t Clinical pharmacology and therapeutics $x 1532-6535 $g Roč. 106, č. 3 (2019), s. 568-575
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30588615 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214130833 $b ABA008
- 999 __
- $a ok $b bmc $g 1596007 $s 1114364
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 106 $c 3 $d 568-575 $e 20190301 $i 1532-6535 $m Clinical pharmacology & therapeutics $n Clin Pharmacol Ther $x MED00001155
- GRA __
- $a NV16-27317A $p MZ0
- LZP __
- $a Pubmed-20201125